Literature DB >> 22204929

Regulation of physiologic actions of LRRK2: focus on autophagy.

Andrew Ferree1, Maria Guillily, Hu Li, Katelyn Smith, Aki Takashima, Rachel Squillace, Manfred Weigele, James J Collins, Benjamin Wolozin.   

Abstract

BACKGROUND: Mutations in LRRK2 are associated with familial and sporadic Parkinson's disease (PD). Subjects with PD caused by LRRK2 mutations show pleiotropic pathology that can involve inclusions containing α-synuclein, tau or neither protein. The mechanisms by which mutations in LRRK2 lead to this pleiotropic pathology remain unknown.
OBJECTIVES: To investigate mechanisms by which LRRK2 might cause PD.
METHODS: We used systems biology to investigate the transcriptomes from human brains, human blood cells and Caenorhabditis elegans expressing wild-type LRRK2. The role of autophagy was tested in lines of C. elegans expressing LRRK2, V337M tau or both proteins. Neuronal function was measured by quantifying thrashing.
RESULTS: Genes regulating autophagy were coordinately regulated with LRRK2. C. elegans expressing V337M tau showed reduced thrashing, as has been noted previously. Coexpressing mutant LRRK2 (R1441C or G2019S) with V337M tau increased the motor deficits. Treating the lines of C. elegans with an mTOR inhibitor that enhances autophagic flux, ridaforolimus, increased the thrashing behavior to the same level as nontransgenic nematodes.
CONCLUSION: These data support a role for LRRK2 in autophagy, raise the possibility that deficits in autophagy contribute to the pathophysiology of LRRK2, and point to a potential therapeutic approach addressing the pathophysiology of LRRK2 in PD.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22204929      PMCID: PMC3363354          DOI: 10.1159/000332599

Source DB:  PubMed          Journal:  Neurodegener Dis        ISSN: 1660-2854            Impact factor:   2.977


  16 in total

1.  Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity.

Authors:  Andrew B West; Darren J Moore; Catherine Choi; Shaida A Andrabi; Xiaojie Li; Dustin Dikeman; Saskia Biskup; Zhenshui Zhang; Kah-Leong Lim; Valina L Dawson; Ted M Dawson
Journal:  Hum Mol Genet       Date:  2007-01-02       Impact factor: 6.150

2.  Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens.

Authors:  Victor M Rivera; Rachel M Squillace; David Miller; Lori Berk; Scott D Wardwell; Yaoyu Ning; Roy Pollock; Narayana I Narasimhan; John D Iuliucci; Frank Wang; Tim Clackson
Journal:  Mol Cancer Ther       Date:  2011-04-11       Impact factor: 6.261

3.  Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity.

Authors:  Andrew B West; Darren J Moore; Saskia Biskup; Artem Bugayenko; Wanli W Smith; Christopher A Ross; Valina L Dawson; Ted M Dawson
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-03       Impact factor: 11.205

4.  Neurodegeneration and defective neurotransmission in a Caenorhabditis elegans model of tauopathy.

Authors:  Brian C Kraemer; Bin Zhang; James B Leverenz; James H Thomas; John Q Trojanowski; Gerard D Schellenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-18       Impact factor: 11.205

5.  The R1441C mutation of LRRK2 disrupts GTP hydrolysis.

Authors:  Patrick A Lewis; Elisa Greggio; Alexandra Beilina; Shushant Jain; Acacia Baker; Mark R Cookson
Journal:  Biochem Biophys Res Commun       Date:  2007-04-10       Impact factor: 3.575

6.  The Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation.

Authors:  Elisa Greggio; Ibardo Zambrano; Alice Kaganovich; Alexandra Beilina; Jean-Marc Taymans; Veronique Daniëls; Patrick Lewis; Shushant Jain; Jinhui Ding; Ali Syed; Kelly J Thomas; Veerle Baekelandt; Mark R Cookson
Journal:  J Biol Chem       Date:  2008-04-08       Impact factor: 5.157

7.  Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells.

Authors:  Edward D Plowey; Salvatore J Cherra; Yong-Jian Liu; Charleen T Chu
Journal:  J Neurochem       Date:  2008-01-07       Impact factor: 5.372

8.  Kinase activity is required for the toxic effects of mutant LRRK2/dardarin.

Authors:  Elisa Greggio; Shushant Jain; Ann Kingsbury; Rina Bandopadhyay; Patrick Lewis; Alice Kaganovich; Marcel P van der Brug; Alexandra Beilina; Jeff Blackinton; Kelly Jean Thomas; Rili Ahmad; David W Miller; Sashi Kesavapany; Andrew Singleton; Andrew Lees; Robert J Harvey; Kirsten Harvey; Mark R Cookson
Journal:  Neurobiol Dis       Date:  2006-06-05       Impact factor: 5.996

9.  Large-scale mapping and validation of Escherichia coli transcriptional regulation from a compendium of expression profiles.

Authors:  Jeremiah J Faith; Boris Hayete; Joshua T Thaden; Ilaria Mogno; Jamey Wierzbowski; Guillaume Cottarel; Simon Kasif; James J Collins; Timothy S Gardner
Journal:  PLoS Biol       Date:  2007-01       Impact factor: 8.029

Review 10.  Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions.

Authors:  Elisa Greggio; Mark R Cookson
Journal:  ASN Neuro       Date:  2009-04-14       Impact factor: 4.146

View more
  22 in total

1.  Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice.

Authors:  M Yue; K M Hinkle; P Davies; E Trushina; F C Fiesel; T A Christenson; A S Schroeder; L Zhang; E Bowles; B Behrouz; S J Lincoln; J E Beevers; A J Milnerwood; A Kurti; P J McLean; J D Fryer; W Springer; D W Dickson; M J Farrer; H L Melrose
Journal:  Neurobiol Dis       Date:  2015-03-31       Impact factor: 5.996

Review 2.  LRRK2, a puzzling protein: insights into Parkinson's disease pathogenesis.

Authors:  A Raquel Esteves; Russell H Swerdlow; Sandra M Cardoso
Journal:  Exp Neurol       Date:  2014-06-04       Impact factor: 5.330

3.  The p.L302P mutation in the lysosomal enzyme gene SMPD1 is a risk factor for Parkinson disease.

Authors:  Ziv Gan-Or; Laurie J Ozelius; Anat Bar-Shira; Rachel Saunders-Pullman; Anat Mirelman; Ruth Kornreich; Mali Gana-Weisz; Deborah Raymond; Liron Rozenkrantz; Andres Deik; Tanya Gurevich; Susan J Gross; Nicole Schreiber-Agus; Nir Giladi; Susan B Bressman; Avi Orr-Urtreger
Journal:  Neurology       Date:  2013-03-27       Impact factor: 9.910

4.  Regulation of autophagy by LRRK2 in Caenorhabditis elegans.

Authors:  Shamol Saha; Liqun Liu-Yesucevitz; Benjamin Wolozin
Journal:  Neurodegener Dis       Date:  2013-10-31       Impact factor: 2.977

Review 5.  Cellular effects of LRRK2 mutations.

Authors:  Mark R Cookson
Journal:  Biochem Soc Trans       Date:  2012-10       Impact factor: 5.407

Review 6.  Current understanding of LRRK2 in Parkinson's disease: biochemical and structural features and inhibitor design.

Authors:  Soumya Ray; Min Liu
Journal:  Future Med Chem       Date:  2012-09       Impact factor: 3.808

7.  LRRK2 and mitochondria: Recent advances and current views.

Authors:  Alpana Singh; Lianteng Zhi; Hui Zhang
Journal:  Brain Res       Date:  2018-06-09       Impact factor: 3.252

Review 8.  ERKed by LRRK2: a cell biological perspective on hereditary and sporadic Parkinson's disease.

Authors:  Manish Verma; Erin K Steer; Charleen T Chu
Journal:  Biochim Biophys Acta       Date:  2013-11-10

9.  LRRK2: an éminence grise of Wnt-mediated neurogenesis?

Authors:  Daniel C Berwick; Kirsten Harvey
Journal:  Front Cell Neurosci       Date:  2013-05-31       Impact factor: 5.505

10.  A Link between Autophagy and the Pathophysiology of LRRK2 in Parkinson's Disease.

Authors:  Patricia Gómez-Suaga; Elena Fdez; Marian Blanca Ramírez; Sabine Hilfiker
Journal:  Parkinsons Dis       Date:  2012-12-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.